Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection

Clin Infect Dis. 2017 Oct 1;65(7):1218-1221. doi: 10.1093/cid/cix523.

Abstract

NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Neutralizing / therapeutic use*
  • Broadly Neutralizing Antibodies
  • Clostridioides difficile / drug effects*
  • Clostridium Infections / drug therapy*
  • Double-Blind Method
  • Humans
  • Middle Aged
  • Patient Readmission
  • Recurrence

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Broadly Neutralizing Antibodies
  • bezlotoxumab

Associated data

  • ClinicalTrials.gov/NCT01241552
  • ClinicalTrials.gov/NCT01513239